Preoperative Anxiolysis With Intravenous Midazolam on Intraoperative Sevoflurane Gas Consumption

Sponsor
Cukurova University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05371600
Collaborator
(none)
80
1
2
4.4
18.3

Study Details

Study Description

Brief Summary

This prospective, randomized, double-blind, placebo-controlled study is performed after obtaining written informed consent of patients who are scheduled for elective general surgery. After the admission to the preoperative unit 30 minutes before the surgery, The preoperative anxiety of patients is evaluated by The State-Trait Anxiety Inventory (STAI). Patients are randomly assigned to one of two groups in a 1:1 ratio by a computer-generated list. Patients receive midazolam IV at 0.04 mg/kg (group M) and an equal volume of saline IV (group C, control group). Anesthesia is induced with 2mg/kg of IV propofol. At a dose of 0.6 mg/kg, IV rocuronium bromide is given for neuromuscular blockade. Anesthesia is maintained at 2% sevoflurane. At the end of the surgery, anesthesia is terminated and the awake patients are extubated.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

An equal depth of anesthesia is achieved by evaluating an entropy value of 40-50 during the operation. Heart rate, blood pressure, the amount of sevoflurane consumed (ml), end-tidal sevoflurane concentration (%), sevoflurane MAC, inspiratory sevoflurane (%), expiratory sevoflurane (%) are recorded at baseline and 15-minute intervals.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
The Effect of Preoperative Anxiolysis With Intravenous Midazolam on Intraoperative Sevoflurane Gas Consumption: A Prospective Randomized Controlled Study
Anticipated Study Start Date :
May 10, 2022
Anticipated Primary Completion Date :
Sep 10, 2022
Anticipated Study Completion Date :
Sep 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group M

Patients receive midazolam IV at 0.04 mg/kg (group M).

Drug: Midazolam
midazolam IV at 0.04 mg/kg

Placebo Comparator: Group C

Patients receive an equal volume of saline IV (group C, control group).

Other: Saline
an equal volume of saline IV

Outcome Measures

Primary Outcome Measures

  1. Sevoflurane consumption [1 hour]

    The amount of sevoflurane consumed (ml)

Secondary Outcome Measures

  1. end-tidal sevoflurane concentration (%) [1 hour]

    end-tidal sevoflurane concentration (%)

Other Outcome Measures

  1. sevoflurane MAC [1 hour]

    sevoflurane MAC

  2. inspiratory sevoflurane (%) [1 hour]

    inspiratory sevoflurane (%)

  3. expiratory sevoflurane (%) [1 hour]

    expiratory sevoflurane (%)

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiologists physical status 1 and 2

  • patients who are scheduled for elective surgery

  • BMI <30

Exclusion Criteria:
  • history of psychiatric disease

  • use of psychotropic medications

  • neurological disorders

  • cancer

  • chronic pain

  • cardiovascular, respiratory, and hepatic diseases.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Anesthesiology, Cukurova University Faculty of Medicine Adana Turkey 01130

Sponsors and Collaborators

  • Cukurova University

Investigators

  • Principal Investigator: Ersel Gulec, MD, Cukurova University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ersel GULEC, Principal Investigator, Cukurova University
ClinicalTrials.gov Identifier:
NCT05371600
Other Study ID Numbers:
  • 14949
First Posted:
May 12, 2022
Last Update Posted:
May 17, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Ersel GULEC, Principal Investigator, Cukurova University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2022